Weever interferon as well as preparation method and application thereof
By optimizing the interferon in perch IFN-α3-like gene, the interferon in perch IFN-α3 was prepared as an adjuvant and used in combination with Floxobacterium columnar antigen, the problems of low transmission efficiency of oral vaccine antigens in fish and side effects of adjuvant are solved, and the problems of the antigen delivery efficiency of oral vaccines in fish are significantly improved. The protective effect of sea bass on Floxobacterium columnaris.
Patent Information
- Application Number
- CN202410930752.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-11
- Publication Date
- 2024-11-08
AI Technical Summary
In the development of existing oral fish vaccines, antigens are difficult to be efficiently transmitted to the intestinal immune system. The production of adjuvants is complicated and has side effects, which fails to effectively improve the immune effect of fish, especially in the prevention and treatment of flavobacterium perch disease. .
By optimizing the interferon in the sea bass IFN-α3-like gene, a recombinant plasmid was constructed, a recombinant expressed strain was obtained, and a perch interferon in IFN-α3 was prepared, and it was used as an oral vaccine adjuvant for fish and was used in combination with the Floxobacterium columnar antigen.
It improves the protection efficiency of fishes to Floxacin, reduces the complexity and side effects of production operations, enhances the broad spectrum of immune response, and increases the protection effect by 17%.
Smart Images

Figure CN118909078A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of aquatic animal disease prevention and treatment, in particular to the technical field of fish vaccine development, and specifically to sea bass interferon and a preparation method and application thereof. Background Art
[0002] Sea bass (Lateolabrax japonicus) is a common economic fish. With the expansion of aquaculture scale and changes in aquaculture environment, sea bass diseases frequently occur, especially those caused by Flavobacterium columnare. Flavobacterium columnare is a common aquatic pathogen, widely distributed in ponds, lakes, rivers and other water bodies. Its host range is extremely wide, and it can infect fish from multiple families including Cyprinidae, Perchidae, Siluridae, Salmonidae, Heliothisidae, Mugilidae, etc., and present different symptoms of infection. Flavobacterium columnare usually damages the skin, fins and gills of fish, and its clinical symptoms depend on the strength of its toxicity, such as gill rot, ulcers on the body surface, and bleeding. Flavobacterium columnare can also cause high mortality, causing huge economic losses to the fishery and seriously endangering aquaculture.
[0003] Fish vaccines can improve the specific and nonspecific immunity level of aquatic animals. They have many advantages such as no pollution to the environment and no drug residues. They are one of the most effective methods for preventing and treating fish diseases. Fish vaccines can be divided into inactivated vaccines, live attenuated vaccines, subunit vaccines and DNA vaccines according to the preparation method. There are three main ways of vaccination: injection, oral and immersion. For fish, oral vaccination is more convenient than injection and immersion vaccines, saves more labor and has the advantage of not being limited by fish size.
[0004] The main obstacle to the development of oral vaccines for fish is how to deliver antigens to the intestinal immune system more efficiently. The role of adjuvants in vaccines is to increase the surface area of antigens, prolong their retention time in the body, allow antigens to be continuously and slowly released in the fish body, and allow them to fully contact with lymphatic system cells, thereby enhancing the activity of macrophages and plasma cells, enhancing the ability of cell-mediated sensitization, and improving antibody levels. Common adjuvants for oral vaccines for fisheries include polymer microspheres, immune complex stimulators, cholera toxin, Escherichia coli heat-labile enterotoxin and cytokines. The use of these adjuvants requires consideration of the cumbersomeness of adjuvant production operations, usage, price, and external environmental factors, as well as the safety, efficiency, toxicity and side effects of the overall vaccine. An ideal adjuvant should specifically assist vaccines in stimulating the immune system without causing side effects to animals. Immune adjuvants can not only change the type of immunoglobulin, but also change the intensity of immune response, enhance immune response, induce specific immunity in the body, eliminate immune tolerance produced by the body, and reduce immune side effects in the body. Type I and type II interferons found in fish are cytokines that play an important role in innate and acquired immunity, and have multiple effects such as inhibiting cell division, regulating immunity, anti-virus, and anti-tumor. However, there are no reports of using fish interferons as immune adjuvants to successfully prepare oral vaccines and achieve effective immune effects. Summary of the invention
[0005] Based on the above problems, the present invention provides a sea bass interferon IFN-α3. In the present invention, the sea bass interferon IFN-α3-like gene is optimized and connected to a plasmid to construct a recombinant plasmid; the recombinant plasmid is transformed, cultured, positive monoclonal screening, plasmid re-extracted, and monoclonal cultured to obtain a recombinant expression strain, and the recombinant expression strain is activated, expanded, induced to express, and purified to obtain the sea bass interferon IFN-α3. The sea bass interferon IFN-α3 is used as an oral vaccine adjuvant for fish, and the immune effect is more stable and the protection efficiency is higher than that of the simple oral pathogenic bacteria antigen.
[0006] Specifically, the first object of the present invention is to provide a seabass interferon IFN-α3, the amino acid sequence of the seabass interferon IFN-α3 is shown in SEQ ID No.1.
[0007] The second object of the present invention is to provide a nucleic acid molecule encoding the seabass interferon IFN-α3.
[0008] In a preferred embodiment, the nucleotide sequence of the nucleic acid molecule is shown as SEQ ID No.2.
[0009] The third object of the present invention is to provide a recombinant plasmid, which contains the nucleic acid molecule.
[0010] The fourth object of the present invention is to provide a genetically engineered bacterium, wherein the genetically engineered bacterium comprises the recombinant plasmid, or the nucleic acid molecule is integrated into the genome of the genetically engineered bacterium.
[0011] The fifth object of the present invention is to provide a method for preparing the sea bass interferon IFN-α3, comprising the following steps: constructing the recombinant plasmid, transforming the recombinant plasmid, culturing the recombinant plasmid, re-extracting the plasmid, and culturing the monoclonal clone to obtain a recombinant expression strain, activating the recombinant expression strain, expanding the culture, inducing expression, and purifying the recombinant expression strain to obtain the sea bass interferon IFN-α3.
[0012] In a preferred embodiment, the recombinant plasmid is obtained by connecting the nucleic acid molecule to plasmid pET-28a.
[0013] The sixth object of the present invention is to provide the application of the preparation method of the seabass interferon IFN-α3 or the nucleic acid molecule or the recombinant plasmid or the genetically engineered bacteria or the seabass interferon IFN-α3 in the preparation of aquatic animal disease prevention and treatment products.
[0014] In a preferred embodiment, the aquatic animal disease control product is used to prevent and control aquatic animal diseases caused by Flavobacterium columnaris.
[0015] The seventh object of the present invention is to provide an aquatic animal disease prevention and control product, which contains the seabass interferon IFN-α3.
[0016] In a preferred embodiment, the aquatic animal disease prevention and control product is obtained by mixing the seabass interferon IFN-α3 and the columnar bacterium antigen in a mass ratio of 1:10.
[0017] Compared with the prior art, the technical scheme of the present invention has the following beneficial effects: (1) In the present invention, the seabass interferon IFN-α3-like gene is optimized, a recombinant plasmid and a recombinant expression strain are constructed, and the recombinant expression strain is screened and activated, expanded culture, induced expression and purified to obtain seabass interferon IFN-α3. The seabass interferon IFN-α3 is used as a vaccine adjuvant for aquatic animals, especially fish, and can provide broad-spectrum protection for receptors and reduce the risk of aquatic animals being infected with different viruses; compared with conventional fishery vaccine adjuvants, its production operation is simple, the price is low, the safety is higher, and the toxic side effects are smaller; compared with some chemical drugs and antibiotics, the toxic side effects and drug residue problems to aquatic animals can be reduced. (2) In the present invention, the seabass interferon IFN-α3 is used as an adjuvant in combination with the columnar Flavobacterium antigen, and the protective effect on seabass is increased by 17% compared with the columnar Flavobacterium antigen alone. (3) The seabass interferon IFN-α3 of the present invention is an immune cytokine, and therefore not only has a synergistic effect on seabass Flavobacterium columnaris antigens, but also has a certain protective effect on other pathogenic bacteria and viral infections of seabass, further improving the broad-spectrum of the adjuvant. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 The figure is the result of agarose gel electrophoresis after the gene encoding seabass interferon IFN-α3 was digested with restriction endonuclease;
[0019] Figure 2 This is a diagram showing the PCR identification results of the monoclonal colony obtained by cloning and culturing the recombinant plasmid;
[0020] Figure 3 The results of SDS-PAGE electrophoresis of the whole bacterial solution, supernatant and precipitate obtained after induction with different IPTG concentrations;
[0021] Figure 4 The Western Blot results of the whole bacterial solution, supernatant and precipitate obtained after induction with different IPTG concentrations and after running on gel;
[0022] Figure 5 This is a curve diagram showing the change in absorbance of the eluate over time when the target protein is purified by Ni column affinity chromatography;
[0023] Figure 6 This is the result of SDS-PAGE electrophoresis of the eluate collected when purifying the target protein by Ni column affinity chromatography;
[0024] Figure 7 This is the result of Western Blot verification of the eluate collected when purifying the target protein by Ni column affinity chromatography;
[0025] Figure 8 This is the mortality curve of sea bass artificially infected with Flavobacterium columnaris after different feeding treatments. DETAILED DESCRIPTION
[0026] The following content is combined with the embodiments to clearly and completely describe the technical solution of the present application so that those skilled in the art can fully understand the present application. Obviously, the described embodiments are only some preferred embodiments of the present application, rather than all embodiments. Any equivalent transformation or substitution made to the following implementation modes by those of ordinary skill in the art without creative work belongs to the protection scope of the present application.
[0027] The materials and reagents used in this application are from the following sources:
[0028] Plasmid DNA minipreparation kit, KOD Plus NEO KOD-401 (KOD enzyme), 10× PCR Buffer, dNTPs, and DNA marker were purchased from Yubao Bioengineering (Dalian) Co., Ltd. (Dalian TaKaRa Company).
[0029] LB medium: 10 g tryptone, 5 g yeast extract, 10 g sodium chloride (add 20 g agar powder when preparing the plate), dissolved in ddH2O, 1 mol / L NaOH to adjust the pH to 7.0-7.5, make up to 1000 mL, sterilize under high pressure steam at 121°C for 20 min, and store at 4°C for later use.
[0030] Preparation of PBS buffer: 1.44 g Na2HPO4, 0.24 g KH2PO4, 8.0 g NaCl and 0.2 g KCl were dissolved in 800 mL distilled water, the pH was adjusted to 7.4 with hydrochloric acid, and the volume was made up to 1000 mL with distilled water.
[0031] Binding buffer composition: 1× phosphate buffer, 20 mM imidazole, pH 7.4.
[0032] Elution buffer composition: 1× phosphate buffer, 40 mM imidazole, pH 7.4.
[0033] The remaining reagents are commercially available analytically pure reagents. The methods not described in detail in the examples are conventional methods well known to those skilled in the art.
[0034] Example 1
[0035] A method for preparing seabass interferon IFN-α3 comprises the following steps:
[0036] 1.1. Construction of recombinant plasmid
[0037] The seabass IFN-α3-like gene sequence (NCBI Reference Sequence: XP_038592064.1) was downloaded from Genbank, and the position of the signal peptide was analyzed using online software (LipoP 1.0 Server). The seabass IFN-α3-like gene sequence fragment was optimized according to the preference of Escherichia coli codons. The nucleotide sequence of the optimized gene is shown in SEQ ID No. 2, and the length is 555 bp. The protein encoded by the nucleotide sequence is a new type of seabass interferon, called seabass interferon IFN-α3. The amino acid sequence of the seabass interferon IFN-α3 is shown in SEQ ID No. 1.
[0038] The artificially synthesized gene sequence shown in SEQ ID No. 2 was digested with BamHI and EcoRI restriction enzymes. The digestion results are shown in Figure 1 shown. Figure 1 The upper M lane is a DNA marker, and lanes 1 to 3 are the products of IFN-α3 coding gene (target gene) digestion. Figure 1 The PCR amplification band of the target gene can be seen on the PCR amplification band. The plasmid pET-28a (purchased from QIAGEN, catalog number: hz-955) was digested with the same BamHI and EcoRI restriction endonucleases. The digested product of the gene shown in SEQ ID No. 2 was ligated with the digested pET-28a (linearized plasmid) to obtain the recombinant plasmid pET28a-IFN-α3.
[0039] PCR amplification system of the gene shown in SEQ ID No.2: 5 μL 10×PCR Buffer, 5 μL 2mM dNTPs, 3 μL 25mM MgSO4, 1.5 μL 0.5 μmol / L forward primer (sequence shown in SEQ ID No.3), 1.5 μL 0.5 μmol / L reverse primer (sequence shown in SEQ ID No.4), 2 μL plasmid (with capsid protein gene), 1 μL KOD enzyme (5U / μL), and ddH2O was used to make up the total volume to 50 μL. PCR reaction program: 94℃ pre-denaturation for 2min; 94℃ denaturation for 10s, 55℃ annealing for 30s, 68℃ extension for 30s, 35 cycles; and finally 68℃ extension for 5min.
[0040] Enzyme digestion reaction system: Prepare on ice, 2 μL BamHI (Thermo Scientific TM , FastDigest BamHI, Catalog No.: FD0055), 2μL EcoRI (Thermo Scientific TM,), 5 μL 10× Buffer, 13 μL linearized plasmid or target gene, and add ddH2O to make the total volume 50 μL.
[0041] Construction of recombinant plasmids by one-step cloning:
[0042] Prepare the reaction system on ice: 1 μL linearized plasmid, 3 μL target gene, 2 μL 5×CEII Buffer, and add ddH2O to a total volume of 10 μL. Use a pipette to gently mix (do not oscillate), centrifuge briefly to collect the reaction solution to the bottom of the tube, heat the lid at 47°C, and react at 37°C for 30 minutes.
[0043] 1.2. Construction of recombinant expression strain (genetically engineered bacteria)
[0044] Transform the recombinant plasmid constructed in step 1.1 into competent cells DH5α, take 100 μL and apply it on 300 μL LB plate with Kana resistance, put it in the incubator, and culture it at 37℃ for 12 hours. After the colonies grow, pick out single clones (3) for PCR identification. The identification results are as follows: Figure 2 shown. Figure 2 The upper M is the DNA Marker lane, and 1 to 3 represent the three selected monoclonal colonies. Figure 2 As can be seen from the figure, after picking 3 single colonies and culturing them in 300 μL of culture medium plus kanamycin for 12 hours, the bacterial solution was subjected to PCR amplification, and the PCR products were subjected to liposome gel electrophoresis. Clear target bands were visible on the electrophoresis diagram.
[0045] The PCR reaction system is as follows: 20-30 ng template (monoclonal bacteria), 25 μL 2×Phanta Flash MasterMix, 2 μL 10 μmol / L forward primer, 2 μL 10 μmol / L reverse primer, and ddH2O is used to make up the total volume to 50 μL. The sequences of the forward and reverse primers for PCR amplification are shown in SEQ ID No. 3 and SEQ ID No. 4, respectively.
[0046] The PCR reaction program is shown in Table 1.
[0047] Table 1 Monoclonal colony PCR identification reaction procedures
[0048]
[0049] The qualified monoclonal colonies identified by PCR were shaken at 37°C and 220rpm for 8 hours, and the recombinant plasmid pET28a-IFN-α3 was extracted using a plasmid DNA small-scale extraction kit, and its concentration was detected to be 233ng / μL. The extracted recombinant plasmid pET28a-IFN-α3 was transferred into the competent cell BL21, and 100μL of the obtained bacterial solution was applied to the LB solid medium with Kana resistance and cultured at 37°C for 12h. After the colonies grew, single colonies were picked and placed in 300mL LB liquid medium containing Kana resistance, and shaken at 37°C and 220rpm for 8h. The bacterial solution was mixed with 50% glycerol in a volume ratio of 1:1 and stored at -80°C.
[0050] 1.3. Induced expression of recombinant expression strains
[0051] 1.3.1. Determine the optimal induction conditions for the recombinant expression strain
[0052] Take 0.3 mL of the bacterial suspension of the recombinant expression strain constructed in step 1.2 and place it in 300 mL of LB liquid medium containing kanamycin sulfate. Incubate at 37°C and 220 rpm until the OD 600nm The concentration of IPTG was 0.6-1.0, and the final concentrations of IPTG were 0mM, 0.5Mm, and 1mM, respectively. The cells were cultured for 12 hours at 16°C, centrifuged at 3500rpm for 20 minutes, the culture medium was discarded, and the cells were resuspended in PBS buffer. The cells were broken with an ultrasonic cell disruptor. When the bacterial solution turned slightly yellow and clear, it was completely broken. The broken bacterial solution was centrifuged at 4°C to separate the supernatant and the precipitate. The whole bacterial solution, the separated supernatant, and the precipitate were sampled separately, and verified by SDS-PAGE and Western Blot to determine the optimal induction conditions. The test results are shown in Figure 3 and Figure 4 .from Figure 3 and Figure 4 As can be seen from the above, the best induction conditions are a final IPTG concentration of 1 mM, a temperature of 16°C, and an induction time of 12 h.
[0053] 1.3.2. Target protein expression and purification
[0054] The recombinant expression strain constructed in step 1.2 was activated overnight. The next day, the activated bacterial solution and Kana antibiotic were propagated to 15 mL of LB liquid medium at a volume ratio of 1000:1. The culture was shaken at 37°C and 200 rpm for 6-8 hours. 15 mL of bacterial solution was added to 1.5 L of LB medium at a ratio of 1:100 (volume ratio) and propagated for about 3 hours. 600nmThe value is 0.6-1.0, and the bacterial growth reaches the logarithmic growth phase. Induce expression according to the optimal induction conditions selected in step 1.3.1. After induction, centrifuge at 4°C and 3500rpm for 20min, collect the bacteria, resuspend with an appropriate amount of binding buffer, and mix by blowing. The resuspended bacterial solution is broken in an ultrasonic disruptor until the solution is clear and slightly yellow. The expressed target protein contains a 6×His tag, so Ni column affinity chromatography is used to purify the target protein. Centrifuge the broken bacterial solution at 4°C, separate the supernatant, and filter with a 0.45μm filter membrane to remove the bacteria and impurities. Incubate the filtered supernatant with the Ni column filler at room temperature to fully bind the target protein to the filler, wash away the impurities with a low concentration of imidazole buffer (Binding buffer), and then elute with a high concentration of imidazole elution buffer (Elution buffer). During the elution process, collect the eluate at each stage. When the stage of washing away impurities is almost over, connect the eluate to a UV detector and determine whether the protein has been eluted based on the absorbance value displayed by the instrument. Figure 5 As shown in the figure, the eluate can be collected starting from 00:04, and the collection can be stopped after the elution peak is stable. The collected eluate is concentrated by organic concentration and then sampled. The collected samples are tested and verified by SDS-PAGE and Western Blot. Figure 6 and Figure 7 As shown, the size of the purified protein is about 40 kDa, which is consistent with the predicted result, and the protein expression is correct. The correctly expressed protein is sea bass interferon IFN-α3 (or called new sea bass interferon). The specific concentration of the purified protein was determined using a BCA protein quantification kit (Shanghai Yamei Biopharmaceutical Technology Co., Ltd., see the kit manual for specific operations), marked, and stored at -80°C.
[0055] Example 2
[0056] The novel seabass interferon prepared in Example 1 was used as an adjuvant in combination with a columnar Flavobacterium antigen to prevent columnar Flavobacterium infection in seabass.
[0057] Experimental fish: 300 sea bass, with an average total length of 10±1cm and an average weight of 18±1g. After relevant virus detection and bacterial isolation confirmed that they were pathogen-free, they were temporarily kept in fully automatic closed-circulation water barrels, with a stocking density of 30 per barrel, oxygenated, and a water temperature of 28±0.5℃.
[0058] The novel seabass interferon and columnar Flavobacterium antigen were mixed evenly at a mass ratio of 1:10. The columnar Flavobacterium antigen was a high temperature inactivated Flavobacterium prepared by Wuhan Huayang Animal Health Group (inactivated with 0.1% formaldehyde at 37°C for 48h).
[0059] Oral vaccine usage: add 1 mg of a mixture of new sea bass interferon and inactivated Flavobacterium columnaris or inactivated Flavobacterium columnaris to every 40 kg of feed. Dissolve inactivated Flavobacterium columnaris or a mixture of new sea bass interferon and inactivated Flavobacterium columnaris in appropriate amount of water, mix well, spray evenly on the feed, and dry.
[0060] Feeding amount for sea bass: Each sea bass weighs 18±1g. Feed 1% of the fish body weight once in the morning and evening, that is, the daily feeding amount is 2% of the fish body weight.
[0061] Required consumables: 0.22μm filter screen, 1mL and 2.5mL syringes, 1.5mL EP tube, sterile saline, tissue homogenizer, heating rod, thermometer, and scoop net.
[0062] Experimental methods and results: Healthy seabass were randomly divided into control group A (unimmunized group), control group B (oral immunization group with inactivated Flavobacterium columnaris alone), and experimental group C (oral immunization group with a combination of novel seabass interferon and inactivated Flavobacterium columnaris). Each of the three groups had a parallel control, with 50 fish in each group. Three days before the artificial infection experiment with Flavobacterium columnaris on seabass, control group A was fed with pure feed; control group B was fed with mixed feed carrying inactivated Flavobacterium columnaris; experimental group C was fed with mixed feed carrying a mixture of novel seabass interferon and inactivated Flavobacterium columnaris; the feeding was continued for 3 days, once in the morning and once in the evening. On the 4th day, the control group and the experimental group were intraperitoneally injected with 0.3 mL of the drug, with a concentration of 4.4×10 6 The test fish were fed with 100 copies / μL of Flavobacterium columnaris (isolated, identified and preserved by the laboratory of Wuhan Huayang Animal Pharmaceutical Co., Ltd.), followed by 30 consecutive days of routine feeding observation, and the incidence and mortality of the test fish were recorded. The observation and record results are shown in Table 2, and the mortality curve is shown in Figure 8 .
[0063] Table 2 Statistical results of mortality in sea bass artificially infected with Flavobacterium columnaris
[0064]
[0065] In Table 2, the protection rate of oral vaccine in control group B = (mortality rate of control group A - mortality rate of control group B) / mortality rate of control group A × 100%, and the protection rate of experimental group C = (mortality rate of control group A - mortality rate of experimental group C) / mortality rate of control group A × 100%. From Table 2 and Figure 8It can be seen that after feeding the pathogen-free healthy sea bass with the mixture of the new sea bass interferon and the inactivated bacteria of Flavobacterium columnaris, and then artificially infecting Flavobacterium columnaris, the test sea bass began to die on the 3rd day after infection, and the death outbreak period was on the 7th day after infection, after which the number began to decline, and the number of deaths on the 21st day was 0. Compared with the oral vaccination with inactivated bacteria of Flavobacterium columnaris alone, the protective effect of oral immunization using the new sea bass interferon as an adjuvant combined with inactivated bacteria of Flavobacterium columnaris increased by 17%.
[0066] The above-described embodiments are only preferred embodiments of the present application and are not intended to limit the scope of protection of the present application. For any person skilled in the art, the present application may have various changes and modifications. Any simple equivalent changes and modifications made based on the scope of protection of the present application and the contents of the specification should be included in the scope of protection of the present application.
Claims
1. A seabass interferon IFN-α3, characterized in that: The amino acid sequence of the seabass interferon IFN-α3 is shown in SEQ ID No.
1.
2. A nucleic acid molecule encoding the seabass interferon IFN-α3 according to claim 1.
3. The nucleic acid molecule according to claim 2, characterized in that The nucleotide sequence of the nucleic acid molecule is shown as SEQ ID No.
2.
4. A recombinant plasmid, characterized in that: The recombinant plasmid comprises the nucleic acid molecule according to claim 2 or claim 3.
5. A genetically engineered bacterium, characterized in that: The genetically engineered bacteria comprises the recombinant plasmid described in claim 4; or the nucleic acid molecule described in claim 2 or claim 3 is integrated into the genome of the genetically engineered bacteria.
6. The method for preparing seabass interferon IFN-α3 according to claim 1, characterized in that: The method comprises the following steps: constructing the recombinant plasmid described in claim 4, subjecting the recombinant plasmid to transformation, culture, positive screening, plasmid re-extraction, and monoclonal culture to obtain a recombinant expression strain, and subjecting the recombinant expression strain to activation, expanded culture, induced expression, and purification to obtain the sea bass interferon IFN-α3.
7. The preparation method according to claim 6, characterized in that: The recombinant plasmid is obtained by connecting the nucleic acid molecule according to claim 2 or claim 3 to the plasmid pET-28a.
8. Use of the seabass interferon IFN-α3 according to claim 1, the nucleic acid molecule according to claim 2, the recombinant plasmid according to claim 4, the genetically engineered bacteria according to claim 5, or the preparation method according to claim 6 in preparing aquatic animal disease prevention and treatment products.
9. A product for preventing and treating aquatic animal diseases, characterized in that: The aquatic animal disease prevention and treatment product includes the seabass interferon IFN-α3 described in claim 1.
10. The aquatic animal disease prevention and treatment product according to claim 9, characterized in that: The aquatic animal disease prevention and treatment product is obtained by mixing the seabass interferon IFN-α3 and the columnar bacterium antigen in a mass ratio of 1:10.
Citation Information
Cited By
Gene, protein, recombinant expression vector, recombinant bacterium and application of fish interferon
CN119709766A
